SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ — DxPrime, an AI-powered solution designed to enhance diagnostic accuracy through real-time integrity analysis and automated code translation, is now available on Mayo Clinic Platform.

Driven by AESOP Technology‘s Clinical Deep Reasoning Network Model, DxPrime customizes its insights based on specialty, gender, and clinical context to ensure diagnostic completeness and precision. It delivers explainable, real-time diagnostic feedback and automatically converts diagnoses into medical codes to reduce misses, delays, or inaccuracies throughout the process from diagnosis to documentation.

DxPrime also supports surgical coding and the detection of left-right laterality mismatches. By identifying diagnostic gaps early and automating diagnostic workflows, it helps physicians to focus more on diagnosing and treating patients while significantly reducing administrative burden.

“After participating in the Mayo Clinic Platform_Accelerate program in 2022, we have continued to refine the core model behind DxPrime to enable physicians to make faster, more accurate decisions with fewer distractions,” said Jim Long, CEO of AESOP Technology. “In an era of increasingly complex diseases and growing workforce shortages, this mission is more critical than ever. We are proud that DxPrime is now a qualified solution on the Mayo Clinic Platform, ready to support over 52,000 physicians around the world across the Mayo Clinic Care Network in delivering better and safer care.”

Mayo Clinic Platform_Solutions Studio accelerates the development and deployment of digital health solutions by offering access to global, federated de-identified data and scalable integration into clinical workflows. The program evaluates each solution for intended use, proposed value, and clinical and algorithmic performance providing transparency and credibility and enabling adoption of transformative health technologies.

“Working with Mayo Clinic Platform speeds up digital healthcare innovation,” said Steve Bethke, Vice President of Solution Developer Market at Mayo Clinic Platform. “It gives digital health companies the tools, data, and capabilities they need to more efficiently and effectively develop and deploy AI and data-centric solutions. When a solution is qualified, providers can trust it has been reviewed for adherence to responsible AI principles, all aimed at supporting care teams and improving patient outcomes.”

About AESOP Technology 

AESOP Technology harnesses the power of AI to revolutionize clinical decision-making through its Clinical Diagnostic Reasoning Network model. By enhancing the accuracy of diagnoses, medication prescriptions, and medical coding, AESOP aims to improve patient safety and streamline healthcare processes. Its innovative solutions seamlessly integrate with EHR systems to boost efficiency and minimize errors, setting a new standard in medical care.

Mayo Clinic does not endorse or warrant the third-party products or services made available through Mayo Clinic Platform, including their functionality, quality, or performance. Mayo Clinic expressly disclaims any express or implied warranties on such third-party products or services, including any implied warranties of merchantability, quality, accuracy, fitness for a particular purpose, or noninfringement. All use of these third-party products or services, including applicable rights or remedies, is governed by separate terms with the applicable third-party developers or providers.

HONG KONG, Oct. 21, 2025 /PRNewswire/ — Charming Medical Limited (Nasdaq: MCTA) (the “Company”), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) at a price of $4.00 per share (the “Public Offering Price”). The Class A Ordinary Shares are expected to commence trading on the Nasdaq Capital Market on October 21, 2025, under the ticker symbol “MCTA”. The Offering is expected to close on or about October 22, 2025, subject to the satisfaction of customary closing conditions.

The Company expects to receive an aggregate of gross proceeds of approximately $6.4 million from the Offering, before deducting underwriting discounts and other offering expenses. Additionally, the Company has granted the underwriters an over-allotment option to purchase up to an additional 240,000 Class A Ordinary Shares at the Public Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (the “Over-allotment Option”), exercisable within 45 days from the closing date of the Offering. If the Over-allotment Option is exercised in full, the gross proceeds will amount to approximately $7.36 million, before deducting underwriting discounts and other offering expenses.

The Company intends to use the net proceeds from the Offering for expanding its business and geographic coverage, potential strategic investments and acquisitions, research and development, and for general working capital and corporate purposes.

The Offering is conducted on a firm commitment basis. Cathay Securities, Inc. is acting as the representative of the underwriters for the Offering. Ortoli Rosenstadt LLP, Harney Westwood & Riegels, and Fairbairn Catley Low & Kong are acting as United States, British Virgin Islands and Hong Kong SAR counsels to the Company, respectively. Kaufman & Canoles, P.C. is acting as U.S. counsel to the underwriters for the Offering.

The Offering is being conducted pursuant to the Company’s registration statement on Form F-1 (File No. 333-287258), as amended, previously filed with, and subsequently declared effective by the United States Securities and Exchange Commission (the “SEC”) on September 30, 2025. The Offering is being made only by means of a prospectus, forming a part of the effective registration statement. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, electronic copies of the prospectus relating to the Offering may be obtained from Cathay Securities, Inc., by standard mail to 40 Wall St., Suite 3600, New York, NY 10005, United States, Attention: Shell Li, or via email at service@cathaysecurities.com, or telephone at +1 (855) 939-3888. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Charming Medical Limited (Nasdaq: MCTA)

Charming Medical Limited (the “Company”) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. The Company integrates TCM principles with modern technology to enhance quality of life and promote holistic well-being. Through its four wellness centers in Hong Kong, the Company offers a wide range of services, including womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional abdominal binding, designed to address women’s health issues such as menstrual irregularities, hormonal imbalance, and postpartum recovery. Under its “Beauty Lab” brand, Charming Medical also develops and distributes TCM-inspired supplements and beauty products, such as uterine care patches, probiotic washes, and nourishing herbal formulations, aimed at improving women’s constitution and vitality. In addition, the Company provides technical training, dietary therapy consultancy, and franchise opportunities to extend its wellness philosophy to other practitioners and entrepreneurs. For more information, please visit https://charmingmed.com.

Forward-Looking Statement

Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company’s statements regarding the expected trading of its Class A Ordinary Shares on the Nasdaq Capital Market, the timing and completion of the Offering, the satisfaction of closing conditions, the exercise of the over-allotment option, the amount of proceeds to be received, the Company’s intended use of proceeds, and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.